The role of altered microRNA expression in premalignant and malignant head and neck lesions with epithelial origin

Aliieh Farshbaf | Farnaz Mohajertehran | Amirhossein Sahebkar | Yasaman Garmei | Parisa Sabbagh | Nooshin Mohtasham

1Dental Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
2Department of Oral and Maxillofacial Pathology, School of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran
3Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
4Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
5Department of Biology, Faculty of Science, Sistan and Balouchestan University, Zahedan, Iran

Correspondence
Nooshin Mohtasham, Department of Oral and Maxillofacial Pathology, School of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran. P.O Box: 9177948959, Mashhad, Iran.
Email: mohtashamn@mums.ac.ir

Abstract

**Background and Aims:** The premalignant lesions of the oral cavity carry a risk of transformation to malignancy. Hence, early diagnosis followed by timely intervention remarkably affects the prognosis of patients. During tumorigenesis, particular microRNAs (miRNAs) show altered expressions and because of their post transcriptionally regulatory role could provide favorable diagnostic, therapeutic, or prognostic values in head and neck cancers.

**Methods:** In this review, we have demonstrated diagnostic, prognostic, and potential therapeutic roles of some miRNAs associated with oral premalignant and malignant lesions based on previous validate studies.

**Results:** It is previously documented that dysregulation of miRNAs contributes to cancer development and progression. MiRNAs could be tumor suppressors that normally suppress cell proliferation, differentiation, and apoptosis or play as oncogenes that improved tumorigenesis process. Altered expression of miRNAs has also been reported in premalignant oral epithelial lesions such as leukoplakia, oral submucous fibrosis, oral lichen planus and some malignant carcinoma like oral squamous cell, verrucous, spindle cell, Merkel cell carcinoma and basal cell.

**Conclusion:** Some of miRNAs could be new therapeutic candidates in miRNA-based target gene therapy. Although more investigations are required to identify the most favorable miRNA candidate, altered expression of some miRNAs could be used as biomarkers in premalignant lesions and oral cancers with high sensitivity and specificity.

**KEYWORDS**
biomarker, microRNA, oral cavity, oral potentially malignant disorders

1 | INTRODUCTION

The in-situ lesions of the oral cavity are considered premalignant with a variant tendency to develop into malignant tumors. Also, oral malignant disorders are locally invasive and carry a risk of distant metastasis. Hence, early diagnosis followed by timely intervention remarkably affects the prognosis of these patients. The oral cavity in-situ lesions with epithelial origin include proliferative verrucous leukoplakia (PVL), erythroplakia, oral submucous fibrosis, erythroleukoplakia, granular leukoplakia, laryngeal keratosis, actinic cheilosis,
and lichen planus (LP). And also oral and maxillofacial malignant tumors are squamous cell carcinoma (SCC), verrucous carcinoma, oropharyngeal carcinoma, spindle cell carcinoma (sarcomatoid SCC, polypoid SCC, carcinosarcoma, pseudosarcoma), adenosquamous carcinoma, basaloïd SCC, carcinoma of the maxillary sinus, sinonasal undifferentiated carcinoma, nasopharyngeal carcinoma, basal cell carcinoma, Merkel cell carcinoma and melanoma. Clinically suspected lesions are confirmed by histopathological examination. During the evaluation of cancerous lesions, the expression of some molecular biomarkers could facilitate early diagnosis.

The microRNAs (miRNAs) are a class of noncoding RNAs with 21–23 nucleotides in length which are naturally found in the form of hairpin structures that regulate gene expression by silencing transcription or inhibition of translation. They usually target the 3′ untranslated region (3′ UTR) and to a lesser extent the 5′ UTR to accelerate degradation of certain mRNAs. Also, miRNAs mediate cellular proliferation, differentiation, and apoptosis, among others. The miRNA synthesis process is schematically demonstrated in Figure 1 that affects extracellular binding proteins and oral epithelial mucosal. MiRNAs are involved in various physiological processes such as differentiation and development, and numerous studies have demonstrated their significant role in several diseases. In human dental tissues, miRNAs may have important functions related to periodontal disease, tooth movement and eruption, dental pulp physiology and pathology, dental cell differentiation, enamel mineralization, and cancerous lesions. Specific miRNA expression profiles have been reported to be predictive of certain clinical outcomes in the oral cavity and could be used as biomarkers for diagnostic and prognostic purposes. Previous studies have highlighted the potential diagnostic role of miRNAs in the management of oral diseases and cancerous lesions. In this review, we have described some alternations in the expression profile of miRNAs that can apply as novel biomarkers in disease control and predicted survival in head and neck premalignant and malignant lesions. The aim of this study is a description of the remarkable role of some miRNAs as diagnostic, prognostic biomarkers, and a potential candidate in therapeutic approaches of different head and neck lesions. In this manner, the miRNA types and their target genes with function are mentioned to highlight their alternation involved in lesion pathogenesis.

2 THE PREMALIGNANT ORAL EPITHELIAL LESIONS

2.1 Leukoplakia (leukokeratosis, erythroleukoplakia, erythroplakia)

Leukoplakia is a precancerous lesion that has histopathologic features, including hyperkeratosis with or without acanthosis. Some leukoplakias show epithelial atrophy. Epithelial dysplasia or carcinoma is found in about 5%–25% of oral leukoplakia. Dysplastic changes begin in the basal and suprabasal epithelium. They mostly
It is shown that expression of some molecular biomarkers such as miR-2, miR-31, miR-203, and miR-1246 changes following the formation of OSMF, which could be of great significance in the management of this lesion (Table 2).

### 2.3 | Oral lichen planus (OLP)

Lichen planus is a chronic inflammatory disease that may affect skin, genitalia, nails, and oral mucosa. Erosive lichen planus (ELP) is a variant of LP with painful ulcerations that is formed by autoimmune damage of the basal cell layer. The most common lesions of LP are purple papules with irregular borders and a pattern of white lines known as Wickham striae on their surface. Lesions of ELP present as atrophic, erythematous with central ulceration. Histopathologic features include a saw-toothed rete ridge, hydropic degeneration of basal cell layer, and keratinocyte degeneration known as colloid bodies. However, the immunopathology characteristics of LP are not specific. There is also a potential malignant transformation of ELP to squamous cell carcinoma (SCC). Some cases present dysplastic leukoplakia, which is a secondary lichenoid inflammatory infiltrate that resembles OLP. There is an association between hepatitis C and OLP particularly in specific populations of the Mediterranean region that highlights genetic profile and geographical distribution of LP. An overexpression profile in some miRNAs like miRNA-146a/miRNA-155 and miR-150-5p/miR-222-3p stimulate Th1 response in OLP, improve autoimmune disease which supports the contributory

### Table 1  Some studies related to alternation in miRNA expression for Leukoplakia

| miRNA          | The mRNA target gene of miRs                                                                 | miRNA function                                                                 | Pathogenesis associated with miRNA alteration                                                                 | Reference |
|----------------|---------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|-----------|
| miR-450b-5p, miR-129-5p, miR-296-5p | Transcriptional regulation, estrogen signaling pathway, p53 signaling pathway, and RIG-I-like receptor signaling pathway | Discrimination of OLK from OLK-OSCC                                           | miR-129-5p downregulated in medullary thyroid carcinoma and lung cancer cell lines and lung cancer tissues miR-296 overexpressed in prostate cancer miR-296-5p decreased in breast cancer miR-450b-5p upregulated in colorectal cancer | 14        |
| miR-21, miR-31  | HIF                                                                                         | miR-31: it mediate oncogenesis by targeting a molecule that inhibits hypoxia inducing-factor in oral cancer and helps the cells to escape from apoptosis and chemotherapy | miR-31 overexpressed in lung cancer                                                                          | 15        |
| miR-191         |                                                                                             |                                                                                | miR-191 is expressed in breast cancer, prostate cancer, colon cancer, and oral cavity                         | 16        |
| miR-150-5p/miR-222-3p | miR-222-3p: associated with tumor progression and lymph node metastasis                      |                                                                                |                                                                                                               | 17        |

Abbreviation: miRNAs, microRNAs.
role of miRNAs in identification of genes involved in development of OLP (Table 3). Of note, OLP, particularly erosive-atrophic type, has been widely confirmed as a potentially malignant disorder. On the other hand, OLP and SCC are common oral lesions that may have separate causes.36 There are other premalignant oral epithelial lesions with limited research which demonstrate altered miRNA expression including smokeless tobacco use, smokeless tobacco keratosis (snuff pouch; snuff dipper’s lesion; tobacco pouch keratosis; spit tobacco keratosis).2

### 3.1 Oral squamous cell carcinoma (OSCC)

Squamous cell carcinoma represents more than 90% of oral malignancies. Risk factors for malignant transformation include tobacco smoking, alcohol consumption, exposure to UV radiation, occupational exposure to solvent and heavy metal dust, environmental pollutants, iron deficiency, and HPV infection.36–38 As seen in Table 4, the regulation of some biomarkers such as miRNA is significantly disrupted in OSCC. Also, the profile of gene expression changes during OSCC process.32,43 In Table 4, we mentioned some miRNAs like miR-423-5p, miR-146a, miR-21, and target genes that their expression alters significantly in oral squamous cell carcinoma.

### 3.2 Verrucous carcinoma (snuff dipper's cancer; ackerman's tumor)

Verrucous carcinoma, a low-grade SCC that comprises less than 16% of oral cancers, is related to smokeless tobacco use and presents with verruciform surface projections. It may develop from high-risk precancer, PVL and has a better prognosis than SCC with no potential for lymph node or distant metastases. In addition to some immunopathologic markers, there are some molecular biomarkers for diagnosis of verrucous carcinoma namely miRNA-195 which downregulates the expression of CDK6 gene.34 Alteration in the expression of miRNA-195 provides a double edge role as a tumor suppressor or oncogene factor that affects multiple pathways including proliferation, metastasis, and apoptosis. In this manner, it involved in a broad range of cancers such as promoting tumorigenesis in gastric, hepatocellular, esophageal, brain, bone cancer, lung, skin, prostate, and cervical cancers.45

### 3.3 Spindle cell carcinoma

Spindle cell carcinoma is a rare OSCC characterized by dysplastic epithelium and invasive spindle elements which are strongly associated with alcohol consumption and tobacco smoking. Spindle cell carcinoma of aerodigestive tract is found in the upper aerodigestive tract particularly in larynx, alveolar mucosa, tongue, buccal mucosa, and lower lip. Previously, dysregulation of miR-200...
| miRNA | The mRNA target gene of miRs | miRNA function | Pathogenesis associated with miRNA alteration | Reference |
|-------|-----------------------------|----------------|---------------------------------------------|-----------|
| miR-26a/b | miR-26a/b inhibited apoptosis with PKCδ and suppressed Th1-related cytokines secretion | miR-26a/b down regulated in metabolic disease and cancer | 26 |
| miR-146a, miR-155 | Both target transcripts that affect the differentiation of CD4+ T cells following Th1 or Th2 responses | miR-146a and miR-155 increased Th1 response in OLP in response to an unknown autoantigen, providing the imbalance of Th1/Th2 cytokines toward Th1immunity (IFN-γ production) which stimulates local immune responses against an antigen in disease progression. | Alteration in expression of miR-146a and miR-155 in chronic inflammatory situations such as periodontal diseases, rheumatoid arthritis, and Sjogren's syndrome | 27,28 |
| miR-155 | Target genes associated with inflammation | miR-155 associated with inflammation, immune responses, tumor development, functioning mainly as a tumor-promoting factor | Overexpression of miR-155 in breast, colon, cervical, and lung cancer | 29 |
| miR-27b-3p | cypd, grem1, litaf, tmsb10, itga5, and mesdc1 | Downregulation of miR-27b-3p inhibited epithelial keratinocytes apoptosis in OLP with upregulation of cyclophilin D expression. Then increased Bcl2 which suppressed caspase activation and cyt C release. | Breast cancer | 30 |
| miR-21, miR-125b, miR-203, miR15b | p53, p63 | miR-21 has an antiapoptotic role with increasing cell proliferation miR-125b suppressing p53 and TNF-α pathway28 miR15b improving induction of regulatory T-cells (Immune regulation) 14 | miR-21: breast, lung and colon cancers miR-125b: Psoriasis, prostate cancer miR-15b: breast cancer miR-203: chronic inflammatory skin diseases such as psoriasis and atopic eczema | 31,32 |
| miR-138 | cyclin D1 (CCND1) | The precursor of miR-138 is expressed ubiquitously, the mature product is found only in specific cell types | HNSCC, nasopharyngeal carcinoma (NPC) Brain cancer | 33 |
| miR-802 | Bcl-2 | It regulates apoptosis of cancer cells | Gastric cancer, tongue squamous cell carcinoma, epithelialmesenchymal transition, and liver | 34 |
| miR-122, miR-199a-3p | miR-122: Akt, LC3B, IGF1 miR-199a-3p: mTOR, LC3B | miR-122: tumor suppressor and has a critical role in inhibiting the tumorigenesis and angiogenesis miR-199a-3p: can modulate cell proliferation by inhibiting mTOR expression | miR-122: breast cancer | 35 |

Abbreviations: miRNAs, microRNAs; OLP, oral lichen planus.
family and miR-205 target classic E- and N-cadherins which mediate epithelial-mesenchymal transition were reported in pancreatic cancer. These miRNAs are also found to be downregulated in spindle cell carcinoma.46

### 3.4 | Basal cell carcinoma (basal cell epithelioma, rodent ulcer)

Basal cell carcinoma (BCC) is the most common skin cancer that frequently arises from basal cells of the epithelium layer in the head and neck region. The main known risk factor is UV radiation but mutations in melanocortin 1 receptor (MC1R) gene or hedgehog pathway genes (e.g., patched (PTCH1) and activation of smoothened (SMO) also enhance susceptibility to BCC.47 Untreated lesions manifest as rodent ulcers. Subtypes include nodulocystic, pigmented, keratotic, adenoid, superficial, infiltrative, morphea form, and micronodular. In Table 5, we have listed alternations in the expression of miRNAs found in BCC.

### 3.5 | Merkel cell carcinoma

Merkel cell carcinoma is a rare, rapidly progressive neuroendocrine tumor that typically manifests as a painless nodule on the head or neck. Risk factors include exposure to UV radiation, immunosuppressive therapy (e.g. transplant recipients), malignancy, HIV infection, adults older than 70 years. In more than 80% of patients, a trace of a novel Merkel cell polyomavirus genome is reported. Immunohistochemistry for neuroendocrine markers (chromogranin A, synaptophysin, neuron-specific enolase, and CD56) and neurofilament implies Merkel cell origin whereas, nonendocrine epithelial and sarcomatous markers indicate pluripotent stem cells from epidermal or dermal origin.2 Merkel cell carcinoma can be differentiated from metastatic small cell carcinoma of the lung by lack of immunoreactivity for thyroid transcription factor 1 (TTF-1). About 25% of cases develop additional malignancies including SCC of the skin, hematologic malignancies, or adenocarcinomas of the breast or ovaries. Hence, patients with Merkel cell carcinoma should be monitored regularly.2 MiR-34a, which is related to p53-dependent

---

**TABLE 4** List of alternation in expression of some miRNA in OSCC

| miRNA         | The mRNA target gene of miRs                                      | miRNA function                                                                 | Pathogenesis associated with miRNA alteration                                      | Reference |
|---------------|-------------------------------------------------------------------|--------------------------------------------------------------------------------|------------------------------------------------------------------------------------|-----------|
| miR3162, miR-3651, miR-494, miR-3162 let-7d | miR-186 target cell-cycle regulation genes | miR-186 regulate apoptotic response, and is an important marker for diagnosis, prognosis, and therapy in OSCC. When overexpressed in cancer tissue play as an anti-invasion target for therapeutic miR-494 as a tumor suppressor induce cell-cycle arrest, cell senescence, apoptosis, and repress cell proliferation | miR-186 downregulated in non-small cell lung cancer, esophageal cancer, and lung adenocarcinoma. | 39,40   |
| miR-21, miR-191 |                                                                | miR-21 is an oncogenic miR.                                                      | miR-21: it has been significantly upregulated in oral squamous cell carcinoma and premalignant lesions miR-191 is overexpressed in breast cancer, prostate cancer, colon cancer, and oral cavity | 16       |
| miR-191, miR-146a | miR-191: CCAAT, TIMP3                                              | miR-146a: enhance tumorigenesis and also it associates with downregulation of the IL-1 receptor associated with kinase 1 (IRAK1), TNF receptor-associated factor 6 (TRAF6), and NUMB endocytic adapter protein (NUMB) | miR-191: colorectal cancer, breast prostate cancer, and acute myeloid leukemia. miR-146a deregulation has been found in oral cancer. | 41       |
| miR-150-5p/miR-423-5p | miR-150-5p: miTOR-HIF-1alpha, VEGF-Apathway miR-423-5p: TTN-AS1 | Both overexpressed and can apply as predictor for tumor progression             | Both correlated with clinical stage, lymph node metastasis status, and stage       | 17       |

Abbreviations: HNSCC, head and neck squamous cell carcinoma; miRNAs, microRNAs; OSCC, oral squamous cell carcinoma.
apoptosis promotion and cell cycle regulation and is involved in the pathogenesis of Merkel cell carcinoma, is listed in Table 6. However, there are few reports on the immunobiological markers in extremely rare variants of SCC, including papillary squamous cell carcinoma (PSCC) and adenoid (acantholytic) squamous cell carcinoma (AdSCC). But according to the information from the reliable online databases, the articles related to the expression of specific microRNA and PSCC and ASCC lesions as biomarkers has not been published.

### 4.2 | Sinonasal undifferentiated carcinoma (SNUC)

Sinonasal undifferentiated carcinoma is a rare and profoundly aggressive tumor with rapid development and a tendency to metastasize to multiple organs. It sometimes presents following radiotherapy of nasopharyngeal carcinoma or retinoblastoma. Immunohistochemically staining for cytokeratin or epithelial membrane antigen (EMA) is usually positive. The role of miR-21 in tumorigenesis has been previously reported in lung, breast, stomach, prostate, colon, and pancreas cancers. An increased expression of miR-21 is also found in undifferentiated sinonasal carcinoma suggesting its prognostic value in all these malignancies.54

### 4.3 | Nasopharyngeal carcinoma

The nasopharyngeal carcinoma arises from epithelium of nasopharynx. Tobacco smoking, salt fish consumption, EBV infection,
| Lesion type                          | miRNA   | The mRNA target gene of miRs | miRNA function                                                                 | Pathogenesis associated with miRNA alteration                              | Reference |
|-------------------------------------|---------|------------------------------|--------------------------------------------------------------------------------|------------------------------------------------------------------------------|-----------|
| Carcinoma of the maxillary sinus    | miR-204 | EphA7                        | Tumor suppressor                                                               |                                                                               | 55        |
| Nasopharyngeal carcinoma            | miR-150 | EMT                          | miR-150 can modulate the epithelial-mesenchymal-transition property in NPC/HK-1 cells and provide motility and invasion. It plays a pivotal role in NPC tumorigenesis with a potential biomarker. | Myasthenia Gravis, Rheumatoid Arthritis, Gastric Cancer                     | 56        |
| miR-1, miR-let-7, miR-9, miR-26a,   | miR-1:  | PTMA                         | miR-1: Induces carcinoma cell apoptosis                                          |                                                                               | 57        |
| miR-29c, miR-98, miR-124, miR-138,  | miR-9:  | EZH2, c-Myc                   | miR-9: Regulates proliferation, EMT, tumor angiogenesis                        |                                                                               |           |
| miR-184, miR-200, miR-204, miR-216b,| miR-29c: | TIAM1                        | miR-29c: Inhibits cell migration and invasion                                   |                                                                               |           |
| miR-451, miR-10b, miR-18a, miR-18b,| miR-216b: | PKCa, K-Ras                  | miR-216b: Suppresses proliferation and invasion                               |                                                                               |           |
| miR-21, miR-30a, miR-93, miR-141,  | miR-18a: | Dicer1, c-Jun, c-Myc          | miR-18a: Lymph node metastasis                                                 |                                                                               |           |
| miR-144, miR-149, miR-155, miR-205,| miR-144: | PTEN, SPLUNC1                | miR-144: Promotes cell growth                                                  |                                                                               |           |
| miR-214, miR-378, miR-421, miR-663,| miR-149: | E-cadherin                   | miR-149: Increases the capability of metastasis and invasion                   |                                                                               |           |
| miR-155, miR-205, miR-214, miR-378,| miR-30a: | EMT                          | miR-30a: Increases the capability of metastasis and invasion                   |                                                                               |           |
| miR-421, miR-663, p21               | miR-155: | Stimulates cell proliferation, colony formation, cell migration, and invasion | miR-155: Stimulates cell proliferation, colony formation, cell migration, and invasion |                                                                               |           |
|                                    | miR-205: | Attenuates cell apoptosis postirradiation | miR-205: Attenuates cell apoptosis postirradiation |                                                                               |           |
|                                    | miR-214: | Promotes NPC cell proliferation, invasion, and metastasis | miR-214: Promotes NPC cell proliferation, invasion, and metastasis |                                                                               |           |
|                                    | miR-378: | Promotes cell proliferation, colony formation, migration, and invasion | miR-378: Promotes cell proliferation, colony formation, migration, and invasion |                                                                               |           |
|                                    | miR-421: | Induces cell growth and apoptosis resistance | miR-421: Induces cell growth and apoptosis resistance |                                                                               |           |
|                                    | miR-663: | Promotes cellular G1/S transition | miR-663: Promotes cellular G1/S transition |                                                                               |           |
| Lesion type        | miRNA   | The mRNA target gene of miRs | miRNA function                                                                                                                                                                                                 | Pathogenesis associated with miRNA alteration                                                                 | Reference |
|-------------------|---------|-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|-----------|
| miR-135a          | IL-17   | Downregulation of miR-135a associated with development of NPC following IL-17 stimulation of pro-inflammatory cytokine expression |                                                                                                                | Ovarian Cyst and Gallbladder Disease.                                                                          | 58        |
| hsa-miR-16, hsa-miR-34a and hsa-miR-449a | FGF2, LDHA, MET, EZH2, ZEB2, NRF1, TGF-beta and cyclin B1. | hsa-miR-16: Inhibiting the NPC cell proliferation, migration, invasion, metastatic colonization. hsa-miR-34a and hsa-miR-449a: Inhibiting the nasopharyngeal malignancy progression. hsa-miR-34c: Suppressing the growth and metastasis of NPC tumor. hsa-miR-101: Inhibiting the cellular processes, including cell differentiation, development and apoptosis. hsa-miR-142: Suppressing NPC cell proliferation, invasion and metastasis. hsa-miR-504: Inducing the radio-resistance in NPC cells. hsa-miR-774: Promoting the nasopharyngeal malignancy progression. |                                                                                                                | 11        |
| Adenoid cystic carcinoma | miR-23b-3p, mir-29a-3p, mir-101-3p, mir-181a-5p, MIR-140-5p | miR-23b-3p: PTEN, mir-29a-3p: AKT2, mir-101-3p: Pim-1, Survivin, Cyclin D1 and β-catenin, miR-181a-5p: LATS2, MIR-140-5p: Survivin | miR-23b-3p: Upregulation of angiogenesis and vascular permeability. mir-29a-3p: High proliferation. mir-101-3p: tumor suppressor role. mir-181a-5p: oncogenic role. | Affect invasion, proliferation, colony formation and cancer progression in liver, breast, prostate cancers | 59–63     |
| Melanoma          | miR-133a, miR-199b, miR-453, miR-520f, miR-521, miR-551b, miR-126, miR-29c, miR-506, miR-507, and miR-520d, miR-190. | BRAF and NRAS genes, hyper-activation of PI3K/AKT & WNT pathways, ApoE signalling, inactivation of p53 and alterations in CDK4/CDKN2A axis | Upregulation: miR-133a, miR-199b, miR-453, miR-520f, miR-521, and miR-551b, miR-126, miR-29c, miR-506, miR-507, and miR-520d. Downregulation: miR-190, miR-489 and miR-527 | Inducing malignant features | 64        |
| Neuroendocrine carcinoma | miRNA-34a, miRNA-155 and miRNA-21 | miRNA-155 interact with p53 protein as proapoptotic factor | Upregulation: oncogenic role | Improving metastases to lymph nodes Lung cancer | 65        |
and vitamin C deficiency are the predisposing risk factors. It can manifest as neurologic symptoms due to metastasis to CNS. There are three histopathologic subtypes of nasopharyngeal carcinoma including keratinizing SCC, differentiated nonkeratinizing carcinoma, and undifferentiated nonkeratinizing carcinoma (mostly found in HPV-positive cases). Although patients are managed by radiotherapy during the early stages, a combination of chemotherapy and radiation therapy is mostly preferred in advanced stages. Recent therapeutic approaches are based on targeted therapies such as epidermal growth factor receptor inhibitors (EGFR), angiogenesis inhibitors, and immunotherapy against EBV antigens. Also, some miRNAs with significantly altered expression are found to be involved in the pathogenesis of nasopharyngeal carcinoma (Table 7).

**5 | DISCUSSION**

In this review, we presented altered expression of miRNAs in several premalignant and malignant head and neck tumors with epithelial origin. Different miRNAs play either as tumor suppressors that normally suppress cell proliferation, differentiation, and apoptosis or as oncogenes which are produced following gain-of-function alterations in proto-oncogenes and thus contribute to tumorigenesis. Hence, dysfunctional miRNAs exert a potential role as favorable biomarkers in the early diagnosis and prognosis of lesions or miRNA-based target therapies. The miRNA-based therapy is a twofold approach; first, replacement therapy in which synthetic/strategies miRNAs increase or restore the function of tumor suppressor miRNAs, and second, Strategies to inhibit oncogenic miRNAs which are mainly antisense oligonucleotides that silence oncogenic miRNAs, as well as sponging miRNAs, masking miRNAs, and small RNA inhibitors. Recently, small molecule-miRNA associations (SMiR) approaches are found to inhibit miRNA biogenesis or target interaction. Although SMiR association network is expensive and time-consuming, but it is exerted for identifying multiple cancer targets until now. However, unique miRNA has complicated function; one miRNA can target multiple genes and one gene can attach to various miRNAs, but this point is more accentuated when unique miRNA plays a double edge function. It is demonstrated when the expression of specific miRNA is altered in contrast to normal cell expression, they can play an oncogenic role or tumor suppressor function.

In head and neck lesions like OSCC and OSMF, miR-21 is an oncogenic miR that overexpressed in six solid cancers such as breast, lung, prostate, colon, oral cavity and acute myeloid leukemia. It seems miR-21 overexpression reduces survival rate of carcinomas with a shorter disease-free period. In this way, miR-21 showed prognostic value. We describe more details in Tables 2 and 4. As well, miR-31 overexpressed in lung cancer and play an oncogenic role in Leukoplakia and OSMF. It detected in malignancies of lung cells and may play a vital role in oral cancer development and helps the cells to escape from apoptosis and chemotherapy. It seems miR-31 can present a more specific modulator role than miR-21 during...
tumorigenesis process in oral epithelium because altered expression of miR-21s observed in different tissues and can play a role in multiple cancer's molecular pathogenesis. The miR-1246 increases invasion and metastasis by activation of the Wnt/β-catenin pathway, and TGF-β1-induced type I collagen expression. This mechanism provides fibrogenesis in the oral cavity and also impacts liver, breast, and colon cancer progression\textsuperscript{20} (Table 2). It has been proposed that miR-1246 can be a candidate for therapeutic approaches of submucosa fibrosis.\textsuperscript{20} Overexpression of miRNA-146a/miRNA-155 and miR-150-5p/miR-222-3p stimulate Th1 response in OLP in encounter to an unknown autoantigen and manifest the imbalance of Th1/Th2 cytokines like IFN-γ production and also associate with tumor progression and lymph node metastasis. This cascade improves disease progression such as autoimmune disease (e.g., rheumatoid arthritis) (Table 3).\textsuperscript{17,27} The miR-146a overexpressed in oral cancer and enhance tumorigenesis and also it associate with downregulation of NUMB endocytic adapter protein (NUMB), the IL-1 receptor associated with kinase 1 (IRAK1), and TNF receptor-associated factor 6 (TRAF6) (Table 4).\textsuperscript{41}

On the other hand, some miRNAs play a role as tumor suppressors. For example, miR-203 downregulated N-cadherin, vimentin, cell proliferation, and also increased CK19 and E-cadherin proteins. The miR-203 overexpression impedes arecoline-induced epithelial-mesenchymal transition and repressed proliferation-related genes that reported in some cancers such as breast, pancreatic, ovarian, laryngeal, and hepatocellular cancers\textsuperscript{21} (Table 2). Thus, miR-203 can prevents invasion and be a candidate for future therapeutic approaches, because influences cell cycle-related genes, proliferation, and inflammation cascade, and also applied as a prognostic biomarker that affects survival rate in patients. One of the other miRs that are known as tumor suppressor factor are miR-122 that has a critical role in inhibiting the tumorigenesis and angiogenesis in OLP and let-7d that prevent the tumorigenesis process and downregulated in head and neck squamous cell carcinoma (HNSCC) (Tables 3,4).\textsuperscript{35,39} Also miR-204 sole as tumor suppressor that involved in pathogenesis of relative common carcinoma of the maxillary sinus by targeting EphA7 gene.\textsuperscript{55} The dual regulatory role of miRNAs generalizes to different tissues and provides complication in a selection of specific microRNA for therapeutic strategies. It seems induce the expression of miRNA with tumor suppressor function or decrease the expression of miRNA with an oncogenic role can help us to use them as valuable therapeutic biomarkers. In addition to therapeutic approaches, oral miRNAs expression profile could serve as prognostic biomarkers by extracting them from body fluids (e.g., saliva, plasma, and blood) following a disease process or a therapeutic intervention.\textsuperscript{52,75} Prognostic evaluations help us develop effective drugs or detect drug resistance.

6 CONCLUSION

The miRNAs are involved in a wide range of cancer pathogenesis and biogenesis and also can apply for early diagnosis and timely treatment that affect patient survival. The potential role of miRNAs as valuable biomarkers in diagnostic, prognostic, and potential therapeutic strategies in oral cancers can lead to appropriate early diagnosis of precancerous lesions, prevention of malignancy development, and improve disease prognosis. Although more investigations are needed to identify the best-standarized protocol for miRNA isolation, altered expression miRNAs could be used for mentioned strategies in head and neck cancers as biomarkers with high sensitivity and specificity. A comprehensive strategy can help us to discover miRNAs with sufficient specificity and sensitivity for therapeutic approaches.

AUTHOR CONTRIBUTIONS

Alieh Farshbaf: Data curation; investigation; visualization; writing – original draft; writing – review and editing. Farnaz Mohajerteheran: Data curation; investigation; writing – original draft. Amirhossein Sahebkar: Investigation; visualization. Yasaman Garmi: Investigation; visualization. Parisa Sabbagh: Writing – original draft; writing – review and editing; writing – review and editing. Nooshin Mohtasham: Conceptualization; data curation; project administration; validation; visualization; writing – review and editing.

ACKNOWLEDGMENT

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

CONFLICT OF INTEREST

The authors declare no conflict of interest. All authors have read and approved the final version of the manuscript. Dr. Nooshin Mohtasham as corresponding author had full access to all of the data in this study and takes complete responsibility for the integrity of the data and the accuracy of the data analysis.

DATA AVAILABILITY STATEMENT

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

TRANSPARENCY STATEMENT

The lead author Nooshin Mohtasham affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

ORCID

Nooshin Mohtasham http://orcid.org/0000-0002-1262-4668

REFERENCES

1. Ojeda D, Huber MA, Kerr AR. Oral potentially malignant disorders and oral cavity cancer. Dermatol Clin. 2020;38(4):507-521.
2. Neville BW, Damm DD, Allen CM, Chi AC. Oral and maxillofacial pathology. 4th ed. Elsevier Health Sciences; 2015.
3. Yete S, Saranath D. MicroRNAs in oral cancer: biomarkers with clinical potential. Oral Oncol. 2020;110:105002.
4. Yap T, Seers C, Koo K, et al. Non-invasive screening of a microRNA-based dysregulation signature in oral cancer and oral potentially malignant disorders. Oral Oncol. 2019;96:113-120.
5. Menini M, Dellepiane E, Pera F, et al. MicroRNA in implant dentistry: from basic science to clinical application. *Microrna*. 2021;10(1):14-28.

6. Farshbaf A, Mohtasham N, Zare R, Mohajertehran F, Rezaee SA. Potential therapeutic approaches of microRNAs for COVID-19: challenges and opportunities. *J Oral Biol Craniofac Res*. 2021;11(2):132-137.

7. Mazumder S, Datta S, Ray JG, Chaudhuri K, Chatterjee R. Liquid biopsy: miRNA as a potential biomarker in oral cancer. *Cancer Epidemiol*. 2019;58:137-145.

8. Jamali Z, Adi Aminabadi N, Attaran R, Pournagiazar F, Ghertasi Oskouei S, Ahmadpour F. MicroRNAs as prognostic molecular signatures in human head and neck squamous cell carcinoma: A systematic review and meta-analysis. *Oral Oncol*. 2015;51(4):321-331.

9. Sehic A, Tulek A, Khuu C, Nirvani M, Sand LP, Utheim TP. Regulatory roles of microRNAs in human dental tissues. *Gene*. 2017;596:9-18.

10. Kovarikova H, Bubancova I, Laco J, et al. Deregulation of selected miRNAs in sinonasal carcinoma: value of miR-21 as a prognostic biomarker in sinonasal squamous cell carcinoma. *Head Neck*. 2017;39(12):2528-2536.

11. Lao TD, Le TAH. MicroRNAs: biogenesis, functions and potential biomarkers for early screening, prognosis and therapeutic molecular monitoring of nasopharyngeal carcinoma. *Processes*. 2020;8(8):966.

12. Chaturvedi AK, Udaltsova N, Engels EA, et al. Oral leukoplakia and risk of progression to oral cancer: a Population-Based cohort study. *J Natl Cancer Inst*. 2020;112(10):1047-1054.

13. Odell EW. Aneuploidy and loss of heterozygosity as risk markers for malignant transformation in oral mucosa. *Oral Dis*. 2021;27:1993-2007.

14. Chen H, Liu X, Jin Z, et al. A three miRNAs signature for predicting the transformation of oral leukoplakia to oral squamous cell carcinoma. *Am J Cancer Res*. 2018;8(8):1403-1413.

15. Uma Maheswari TN, Niveditha MS, RAMANI P. Expression profile of salivary micro RNA-21 and 31 in oral potentially malignant disorders. *Braz Oral Res*. 2020;34(34):e002.

16. Lakshmi KSSM, Lakshmi KC, Kannan A, et al. Evaluation of novel MicroRNA profile-21 and 191 in oral leukoplakia and oral squamous cell carcinoma in comparison with healthy tissues - A cross-sectional study. *Clin Cancer Investig*. 2021;20(10):275.

17. Chang Y-A, Weng S-L, Yang S-F, et al. A three-miRNA signature as a potential biomarker for the early detection of oral cancer. *Int J Mol Sci*. 2018;19(9):3785.

18. Malimaite A, Abudoukeremou K, Tie L, Pan Y, Li X. MicroRNA expression profiling and functional annotation analysis of their targets associated with the malignant transformation of oral leukoplakia. *Gene*. 2015;558(2):271-277.

19. Shih YH, Wang TH, Shieh TM, Tseng YH. Oral submucous fibrosis: a review on etiopathogenesis, diagnosis, and therapy. *Int J Mol Sci*. 2019;20(2):2940.

20. Liu CM, Liao YW, Hsieh PL, et al. mir-1246 as a therapeutic target in oral submucous fibrosis. *Pathomechanisms of Oral Mucosa*. 2019;118(7):1093-1098.

21. Zheng L, Jian X, Guo F, et al. miR-203 inhibits arecoline-induced epithelial-mesenchymal transition by regulating secreted frizzled-related protein 4 and transmembrane-4 L six family member 1 in oral submucous fibrosis. *Oral Oncol*. 2015;53(6):2753-2760.

22. Prasad SR, Pai A, Shyamala K, Yaji A. Expression of salivary miRNA 21 in Oral Submucous Fibrosis (OSMF): an observational study. *Microrna*. 2021;9(4):295-302.

23. Khan S, Akram Butt S, Hassan S, Khan R. Expression of salivary miRNA-31 in oral submucous fibrosis. *J Adv Med Med Res*. 2021;34:e002.

24. Gall R, Navarro-Fernandez IN. Lichen Planus Erosive Form. *StatPearls*. Treasure Island (FL): StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC; 2021.
45. Yu W, Liang X, Li X, et al. MicroRNA-195: a review of its role in cancers. Onco Targets Ther. 2018;11:7109-7123.

46. Zidar N, Bošiţanjčič E, Gale N, et al. Down-regulation of microRNAs of the miR-200 family and miR-205, and an altered expression of classic and desmosomal cadherins in spindle cell carcinoma of the head and neck—hallmark of epithelial-mesenchymal transition. Hum Pathol. 2011;42(4):482-488.

47. Kim DP, Kus KJB, Ruiz E. Basal cell carcinoma review. Hematol Oncol Clin North Am. 2019;33(1):13-24.

48. Sun H, Jiang P. MicroRNA-451a acts as tumor suppressor in cutaneous basal cell carcinoma. Mol Genet Genomic Med. 2018;6(6):1001-1009.

49. Sand M, Hessam S, Amur S, et al. Expression of oncogenic miR-17-92 and tumor suppressive miR-143-145 clusters in basal cell carcinoma and cutaneous squamous cell carcinoma. J Dermatol Sci. 2017;86(2):142-148.

50. Wan C, Li Y. Integrative analysis of mRNA-miRNA-TFs reveals the key regulatory connections involved in basal cell carcinoma. Arch Dermatol Res. 2020;312(2):133-143.

51. Veja T, Sahi H, Koljonen V, Bohling T, Knuutila S, Mosakhani N. miRNA-34a underepressed in Merkel cell polymavirus-negative Merkel cell carcinoma. Virchows Arch. 2015;466(3):289-295.

52. Fan K, Ritter C, Nghiem P, et al. Circulating cell-free miR-375 as surrogate marker of tumor burden in Merkel cell carcinoma. Clin Cancer Res. 2018;24(23):5873-5882.

53. Fan K, Zebisch A, Horny K, Schrama D, Becker JC. Highly expressed miR-375 is not an intracellular oncogene in Merkel cell polymavirus-associated Merkel cell carcinoma. Cancers. 2020;12(5):529.

54. Abdelmeguid AS, Bell D, Hanna EY. Sinonasal undifferentiated carcinoma. Curr Oncol Rep. 2019;21(3):26.

55. Sun Y, Xu C, Wu Q, Zhang L, Wang P. Long noncoding RNA KCNQ1OT1 promotes proliferation, migration, and invasion in maxillary sinus squamous cell carcinoma by regulating miR-204/EphA7 axis. J Cell Biochem. 2020;121(4):2962-2969.

56. Yue PYK, Hau WY, Lau CC, et al. MicroRNA profiling study reveals miR-150 in association with metastasis in nasopharyngeal carcinoma. Sci Rep. 2017;7(1):12012.

57. Tan G, Tang X, Tang F. The role of microRNAs in nasopharyngeal carcinoma. Tumor Biol. 2015;36(1):69-79.

58. Wang LX, Kang ZP, Yang ZC, et al. MicroRNA-135a inhibits nasopharyngeal carcinoma cell proliferation through targeting Interleukin-1. Cell Physiol Biochem. 2018;46(6):2232-2238.

59. Hou C, Sun N, Han W, et al. Exosomal microRNA-23b-3p promotes tumor angiogenesis and metastasis by targeting PTEN in salivary adenoid cystic carcinoma. Carcinogenesis. 2022;43:682-692.

60. Zhao J, Liu X, Lin J, et al. AKT2 identified as a potential target of miR-29a-3p via microRNA profiling of patients with high proliferation lacrimal gland adenoid cystic carcinoma. Exp Eye Res. 2022;219:109067.

61. Liu XY, Liu ZJ, He H, Zhang C, Wang YL. Erratum: MicroRNA-101-3p suppresses cell proliferation, invasion and enhances chemotherapeutic sensitivity in salivary gland adenoid cystic carcinoma by targeting Pim-1. Am J Cancer Res. 2022;12(2):922-923.

62. Fu R, Wang Y, Wang Y. Silencing microRNA-181a-5p suppresses malignant behavior of lacrimal adenoid cystic carcinoma cells by upregulating large tumor suppressor 2. Int J Clin Exp Pathol. 2020;13(9):2419-2426.

63. Qiao Z, Zou Y, Zhao H. MicroRNA-140-5p inhibits salivary adenoid cystic carcinoma progression and metastasis via targeting survivin. Cancer Cell Int. 2019;19:301.

64. Ghafouri-Fard S, Gholipour M, Taheri M. MicroRNA signature in melanoma: biomarkers and therapeutic targets. Front Oncol. 2021;11:608987.

65. Korotaeva A, Mansorunov D, Apanovich N, Kuzevanova A, Karpukhin A. MiRNA expression in neuroendocrine neoplasms of frequent localizations. noncoding. RNA. 2021;7(3):38.

66. Shaw P, Senthilnathan R, Krishnan S, et al. A clinical update on the prognostic effect of microRNA biomarkers for survival outcome in nasopharyngeal carcinoma: a systematic review and Meta-Analysis. Cancers. 2021;13(17):4369.

67. Islam KA, Chow LKY, Kam NW, et al. Prognostic biomarkers for survival in nasopharyngeal carcinoma: a systematic review of the literature. Cancers. 2022;14(9):2122.

68. Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. The Lancet. 2019;394(10192):64-80.

69. Chen S, Youhong T, Tan Y, et al. EGFR-PKM2 signaling promotes the metastatic potential of nasopharyngeal carcinoma through induction of FOSL1 and ANTXR2. Carcinogenesis. 2020;41(6):723-733.

70. Ali Syeda Z, Langden SSS, Mukhtuzel C, Lee M, Song SJ. Regulatory mechanism of MicroRNA expression in cancer. Int J Mol Sci. 2020;21(5):1723.

71. Mollaei H, Safaralizadeh R, Rostami Z. MicroRNA replacement therapy in cancer. J Cell Physiol. 2019;234(8):12369-12384.

72. Liu F, Peng L, Tian G, et al. Identifying small molecule-miRNA associations based on credible negative sample selection and random walk. Front Bioeng Biotechnol. 2020;8:131.

73. Ashrafizadeh M, Hushmandi K, Hashemi M, et al. Role of microRNA/epithelial-to-mesenchymal transition axis in the metastasis of bladder cancer. Biomolecules. 2020;10(8):1159.

74. Najminejad H, Farhadhosseinabadi B, Dabaghian M, et al. Key regulatory miRNAs and their interplay with mechanosensing and mechanotransduction signaling pathways in breast cancer progression. Mol Cancer Res. 2020;18(8):1113-1128.

75. Diez-Fraile A, Ceulaer JD, Derpoorter C, et al. Circulating non-coding RNAs in head and neck cancer: roles in diagnosis, prognosis, and therapy monitoring. Cells. 2020;10(1):48.

How to cite this article: Farshbaf A, Mohajeretehran F, Sahebkar A, Garmei Y, Sabbagh P, Mohtasham N. The role of altered microRNA expression in premalignant and malignant head and neck lesions with epithelial origin. Health Sci Rep. 2022;5:e921. doi:10.1002/hsr2.921